We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Xi'an Tianlong Science & Technology Co., Ltd

Tianlong is an innovative, high-technology company that provides professional PCR detection devices, reagent kits and... read more Featured Products: More products

Download Mobile App




TianLong HPV Nucleic Acid Detection Kit Could Enable Early Detection of Cervical Cancer

By LabMedica International staff writers
Posted on 02 Feb 2024

Cervical cancer is the second most common cancer after breast cancer to affect women aged 15–44 years in the European Union. More...

Each year, there are around 33 000 cases of cervical cancer in the EU, and 15,000 deaths. The primary cause of cervical cancer is a persistent infection of the genital tract by some specific types of human papillomavirus (HPV). HPV is present in most cases of cervical lesions, which can further develop into cancer.

Vaccination rates and the incidence of cervical adenocarcinoma are both on the rise, making HPV genotype testing an important tool to help stratify risk and guide patient management. High-risk HPV genotypes 16, 18 account for 70% of cervical cancer worldwide. Tianlong’s Human Papillomavirus (HPV) Nucleic Acid Detection Kit is a qualitative in vitro test for detection of 18 high-risk HPV types (HPV 16,18,26,31,33,35,39,45,51,52,53,56,58,59,66,68,73 and 82), which can specifically identify types of HPV 16 and HPV 18 while concurrently detecting the rest of other high-risk types.

Features

  • High Precision:
  • The coefficient of variation of the Ct values (CV%) is less than 5%
  • More accurate:
  • Collocating with Tianlong extraction reagent makes your experiment results more accurate
  • Internal Control:
  • The use of internal control system in the kit can effectively prevent false negative results
  • User-friendly:
  • Applicable in instruments with FAM, HEX/VIC,CY5 and TEXAS RED/ROX channels
  • Concurrently detects remaining 16 HPV genotypes:
  • 26,31,33,35,39,45,51,52,53,56,58,59,66,68,73,82 Positive or Negative Pooled Result


About TianLong

TianLong Science and Technology Co., Ltd.(Shaanxi, China) is a Chinese manufacturer dedicated to molecular diagnosis instruments and kits for over 26 years, with IS013485, CE certificated, providing integrated PCR lab solutions and OEM service.

For more information or inquiries, please contact Tianlong team directly.  

 


New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.